|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...7980818283848586878889...156157» |
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial primary completion date: Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy (clinicaltrials.gov) - Nov 20, 2014
P4, N=54, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Sep 2015
- | olesoxime (TRO19622) / Roche
Trial completion: Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. (clinicaltrials.gov) - Nov 20, 2014
P1, N=44, Completed, Sponsor: Trophos
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Sep 2015 Active, not recruiting --> Completed
- Trial completion: The Predictive Value of Ultrasound in Early Rheumatoid Arthritis (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=150, Completed, Sponsor: Erasmus Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- ibandronate sodium hydrate / Generic mfg.
Trial completion, Trial primary completion date: Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids (clinicaltrials.gov) - Nov 19, 2014
P4, N=167, Completed, Sponsor: Yeong-Wook Song
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Apr 2014
- |||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial primary completion date: DEPICT 1: Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (clinicaltrials.gov) - Nov 19, 2014
P3, N=768, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Apr 2014 Trial primary completion date: Oct 2016 --> May 2017
- Clinical: The Clinical Efficacy of DFPP in Patients With AAGN (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=70, Recruiting, Sponsor: Zhi-Hong Liu, M.D.
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial: A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI) (clinicaltrials.gov) - Nov 19, 2014
P3, N=240, Recruiting, Sponsor: Sanofi
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P1 trial: Mass Balance Study of MT-1303 (clinicaltrials.gov) - Nov 19, 2014
P1, N=9, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Enrollment closed: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Nov 19, 2014
P3, N=500, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Oct 2016 --> May 2017 Recruiting --> Active, not recruiting
- ||| Enrollment closed, Enrollment change: Effect of CSII and CGM on Progression of Late Diabetic Complications (clinicaltrials.gov) - Nov 19, 2014
P4, N=60, Active, not recruiting, Sponsor: Steen Andersen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=80 --> 60
- Trial completion: Alternative Delivery of Dose Adjustment For Normal Eating (DAFNE) Trial in Patients With Type 1 Diabetes (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=170, Completed, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Recruiting --> Active, not recruiting | N=80 --> 60 Active, not recruiting --> Completed
- Cimzia (certolizumab pegol) / Astellas, UCB
New P2 trial: RICE: Remission by Intra-articular Injection Plus CErtolizumab (clinicaltrials.gov) - Nov 18, 2014
P2, N=48, Recruiting, Sponsor: Rüdiger B. Müller
- | GSK2618960 / GSK
New P1 trial: Single Ascending Doses Study of Anti- Interleukin-7 Receptor ? Monoclonal Antibody (GSK2618960) in Healthy Volunteers (clinicaltrials.gov) - Nov 18, 2014
P1, N=18, Not yet recruiting, Sponsor: GlaxoSmithKline
- Enrollment closed: Feasibility Study of PID Versus MPC and HMS (clinicaltrials.gov) - Nov 18, 2014
P0, N=20, Active, not recruiting, Sponsor: William Sansum Diabetes Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Monotherapy: ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=304, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Nov 18, 2014
P3, N=202, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=1229, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Oct 2014
- ||||| Tavalisse (fostamatinib) / Rigel
Trial initiation date: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 17, 2014
P3, N=75, Not yet recruiting, Sponsor: Rigel Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Oct 2014 Initiation date: Jun 2014 --> Nov 2014
- Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment change, Trial withdrawal: Frequency: Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (clinicaltrials.gov) - Nov 17, 2014
P4, N=0, Withdrawn, Sponsor: Biogen Idec
Initiation date: Jun 2014 --> Nov 2014 N=1200 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment open: The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow (clinicaltrials.gov) - Nov 17, 2014
P=N/A, N=21, Recruiting, Sponsor: Radboud University
N=1200 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- insulin peglispro (LY2605541) / Eli Lilly
Enrollment closed: A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements (clinicaltrials.gov) - Nov 17, 2014
P1, N=28, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment closed, Trial primary completion date: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Nov 17, 2014
P3, N=200, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- Clinical: SOCOG-MS: Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 14, 2014
P=N/A, N=35, Not yet recruiting, Sponsor: University Hospital, Bordeaux
- Clinical: DIMMISI: Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS (clinicaltrials.gov) - Nov 14, 2014
P=N/A, N=144, Recruiting, Sponsor: Niguarda Hospital
- |||| atacicept (VT-001) / Vera Therap
Enrollment open: Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) (clinicaltrials.gov) - Nov 14, 2014
P2b, N=213, Recruiting, Sponsor: EMD Serono
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 Not yet recruiting --> Recruiting
- Nucala (mepolizumab) / GSK
Trial primary completion date: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Nov 14, 2014
P2, N=30, Recruiting, Sponsor: University Hospital Inselspital, Berne
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Dec 2016
- | AMG 811 / Amgen
New P1 trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 14, 2014
P1, N=26, Completed, Sponsor: Amgen
- Lantus (insulin glargine) / Sanofi
Enrollment closed: Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus (clinicaltrials.gov) - Nov 14, 2014
P1, N=36, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Oct 2014 --> Dec 2016 Recruiting --> Active, not recruiting
- || Trial primary completion date: SCI-COG: Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=120, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Trial completion, Enrollment change: NEO: An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=154, Completed, Sponsor: Merck KGaA
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | N=254 --> 154
- pioglitazone / Generic mfg.
Trial completion: Inflammation and Insulin Resistance in Rheumatoid Arthritis (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=34, Completed, Sponsor: Vanderbilt University
Active, not recruiting --> Completed | N=254 --> 154 Active, not recruiting --> Completed
- Trial initiation date: Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects (clinicaltrials.gov) - Nov 13, 2014
P2, N=48, Not yet recruiting, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Initiation date: Jan 2014 --> Jan 2015
- Enrollment open: Full Day and Night Closed-Loop With DiAs Platform (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=48, Recruiting, Sponsor: University of Virginia
Initiation date: Jan 2014 --> Jan 2015 Active, not recruiting --> Recruiting
- Enrollment closed: A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1 (clinicaltrials.gov) - Nov 13, 2014
P2, N=13, Active, not recruiting, Sponsor: Profil Institut f
Active, not recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date: COMP-ACT: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX (clinicaltrials.gov) - Nov 12, 2014
P3, N=600, Recruiting, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Feb 2016 --> Aug 2016
- Clinical: STRATEGE: Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=1000, Recruiting, Sponsor: GECEM
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion, Trial primary completion date: Dose-finding Study of MT-1303 (clinicaltrials.gov) - Nov 12, 2014
P2, N=415, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Trial primary completion date: Feb 2016 --> Aug 2016 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jul 2014
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial termination, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 12, 2014
P4, N=2, Terminated, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jul 2014 Completed --> Terminated; The study was stopped prematurely due to lack of enrollment.
- Clinical: Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=40, Recruiting, Sponsor: University Hospital of Ferrara
- Clinical: Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=45, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open, Monotherapy: A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=80, Recruiting, Sponsor: Hoffmann-La Roche
Completed --> Terminated; The study was stopped prematurely due to lack of enrollment. Active, not recruiting --> Recruiting
- || Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Trial primary completion date: An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=135, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Nov 2014
- Clinical: Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis (clinicaltrials.gov) - Nov 11, 2014
P=N/A, N=32, Completed, Sponsor: University of Deusto
- prednisone delayed-release tablet / Generic mfg.
Observational data: SUNRAY: A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 10, 2014
P=N/A, N=60, Enrolling by invitation, Sponsor: Horizon Pharma Ireland, Ltd., Dublin Ireland
- Enrollment open: MGEX: Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=44, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Nov 2014 Not yet recruiting --> Recruiting
- Enrollment closed: Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 7, 2014
P1/2, N=30, Active, not recruiting, Sponsor: Iniciativa Andaluza en Terapias Avanzadas - Fundación Pública Andaluza Progreso y Salud
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial primary completion date: MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=40, Recruiting, Sponsor: Rabin Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- || Trial primary completion date: MD Logic Pump Advisor -Pediatric Study (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Rabin Medical Center
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Jul 2014 --> Jul 2015
- || Trial primary completion date: MD Logic Pump Advisor- Adults Study (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=135, Active, not recruiting, Sponsor: Rabin Medical Center
Trial primary completion date: Jul 2014 --> Jul 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Trial initiation date: The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=150, Not yet recruiting, Sponsor: Rabin Medical Center
Trial primary completion date: Dec 2014 --> Dec 2015 Initiation date: May 2014 --> Dec 2014